OPKO Health, Inc. (OPK)
USD 1.46
(-4.58%)
USD 1.46
(-4.58%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 574.68 Million USD | -26.99% |
| 2022 | 534.4 Million USD | -10.34% |
| 2021 | 596 Million USD | 22.31% |
| 2020 | 487.3 Million USD | -7.36% |
| 2019 | 526 Million USD | -4.69% |
| 2018 | 551.9 Million USD | -11.8% |
| 2017 | 625.74 Million USD | -6.12% |
| 2016 | 666.5 Million USD | 90.47% |
| 2015 | 349.93 Million USD | 129.57% |
| 2014 | 152.43 Million USD | 26.65% |
| 2013 | 120.35 Million USD | 116.27% |
| 2012 | 55.65 Million USD | 64.04% |
| 2011 | 33.92 Million USD | 29.81% |
| 2010 | 26.13 Million USD | -11.71% |
| 2009 | 29.6 Million USD | -22.2% |
| 2008 | 38.04 Million USD | 57.63% |
| 2007 | 24.13 Million USD | 2060.88% |
| 2006 | 1.11 Million USD | -22.32% |
| 2005 | 1.43 Million USD | -29.89% |
| 2004 | 2.05 Million USD | -45.23% |
| 2003 | 3.74 Million USD | -60.92% |
| 2002 | 9.58 Million USD | -19.15% |
| 2001 | 11.85 Million USD | 21.44% |
| 2000 | 9.75 Million USD | 70.43% |
| 1999 | 5.72 Million USD | 33.16% |
| 1998 | 4.3 Million USD | 22.86% |
| 1997 | 3.5 Million USD | 9.38% |
| 1996 | 3.2 Million USD | 77.78% |
| 1995 | 1.8 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 92.1 Million USD | -0.21% |
| 2024 Q2 | 92.9 Million USD | 0.87% |
| 2023 Q2 | 119.48 Million USD | -7.94% |
| 2023 FY | 390.15 Million USD | -26.99% |
| 2023 Q4 | 92.3 Million USD | -18.46% |
| 2023 Q3 | 113.2 Million USD | -5.26% |
| 2023 Q1 | 129.8 Million USD | 12.77% |
| 2022 Q1 | 157.87 Million USD | -8.05% |
| 2022 FY | 534.4 Million USD | -10.34% |
| 2022 Q3 | 119.87 Million USD | -15.29% |
| 2022 Q4 | 115.1 Million USD | -3.98% |
| 2022 Q2 | 141.51 Million USD | -10.36% |
| 2021 Q1 | 144.17 Million USD | 9.31% |
| 2021 Q2 | 144.03 Million USD | -0.1% |
| 2021 Q3 | 136.03 Million USD | -5.55% |
| 2021 Q4 | 171.7 Million USD | 26.22% |
| 2021 FY | 596 Million USD | 22.31% |
| 2020 FY | 487.3 Million USD | -7.36% |
| 2020 Q4 | 131.9 Million USD | -0.28% |
| 2020 Q2 | 110.26 Million USD | -2.27% |
| 2020 Q3 | 132.26 Million USD | 19.95% |
| 2020 Q1 | 112.83 Million USD | -3.97% |
| 2019 Q3 | 126.97 Million USD | -4.66% |
| 2019 Q1 | 148.3 Million USD | 2.35% |
| 2019 Q2 | 133.18 Million USD | -10.2% |
| 2019 Q4 | 117.5 Million USD | -7.46% |
| 2019 FY | 526 Million USD | -4.69% |
| 2018 Q1 | 141.7 Million USD | -25.26% |
| 2018 Q3 | 131.13 Million USD | -2.21% |
| 2018 FY | 551.9 Million USD | -11.8% |
| 2018 Q4 | 144.9 Million USD | 10.5% |
| 2018 Q2 | 134.09 Million USD | -5.37% |
| 2017 Q3 | 181.68 Million USD | 1.57% |
| 2017 FY | 625.74 Million USD | -6.12% |
| 2017 Q4 | 189.6 Million USD | 4.35% |
| 2017 Q2 | 178.88 Million USD | -0.97% |
| 2017 Q1 | 180.63 Million USD | 9.34% |
| 2016 Q4 | 165.2 Million USD | -1.31% |
| 2016 Q3 | 167.4 Million USD | 1.68% |
| 2016 Q1 | 169.26 Million USD | 18.87% |
| 2016 Q2 | 164.63 Million USD | -2.73% |
| 2016 FY | 666.5 Million USD | 90.47% |
| 2015 Q2 | 53.74 Million USD | -24.84% |
| 2015 Q4 | 142.39 Million USD | 73.03% |
| 2015 FY | 349.93 Million USD | 129.57% |
| 2015 Q1 | 71.5 Million USD | 63.68% |
| 2015 Q3 | 82.29 Million USD | 53.12% |
| 2014 Q2 | 33.93 Million USD | -9.63% |
| 2014 FY | 152.43 Million USD | 26.65% |
| 2014 Q4 | 43.68 Million USD | 17.24% |
| 2014 Q1 | 37.55 Million USD | -10.03% |
| 2014 Q3 | 37.26 Million USD | 9.81% |
| 2013 Q2 | 26.12 Million USD | 4.3% |
| 2013 Q3 | 27.44 Million USD | 5.06% |
| 2013 Q1 | 25.04 Million USD | 31.81% |
| 2013 FY | 120.35 Million USD | 116.27% |
| 2013 Q4 | 41.73 Million USD | 52.06% |
| 2012 Q1 | 12.63 Million USD | 24.98% |
| 2012 Q2 | 12.03 Million USD | -4.78% |
| 2012 Q3 | 13.12 Million USD | 9.04% |
| 2012 FY | 55.65 Million USD | 64.04% |
| 2012 Q4 | 19 Million USD | 44.83% |
| 2011 Q3 | 8.59 Million USD | -5.49% |
| 2011 FY | 33.92 Million USD | 29.81% |
| 2011 Q4 | 10.11 Million USD | 17.65% |
| 2011 Q1 | 8.11 Million USD | -18.3% |
| 2011 Q2 | 9.09 Million USD | 12.11% |
| 2010 Q2 | 8.13 Million USD | 25.88% |
| 2010 Q1 | 6.46 Million USD | -20.72% |
| 2010 FY | 26.13 Million USD | -11.71% |
| 2010 Q4 | 9.92 Million USD | 9.24% |
| 2010 Q3 | 9.08 Million USD | 11.76% |
| 2009 Q3 | 6.3 Million USD | 8.06% |
| 2009 Q4 | 8.14 Million USD | 29.33% |
| 2009 Q1 | 9.32 Million USD | -4.22% |
| 2009 FY | 29.6 Million USD | -22.2% |
| 2009 Q2 | 5.83 Million USD | -37.46% |
| 2008 Q4 | 9.73 Million USD | 7.4% |
| 2008 FY | 38.04 Million USD | 57.63% |
| 2008 Q1 | 10.12 Million USD | 11.25% |
| 2008 Q2 | 9.12 Million USD | -9.89% |
| 2008 Q3 | 9.06 Million USD | -0.69% |
| 2007 Q1 | -243.74 Million USD | -51200.42% |
| 2007 Q4 | 9.1 Million USD | 588.04% |
| 2007 Q3 | -1.86 Million USD | -117.31% |
| 2007 Q2 | 10.77 Million USD | 104.42% |
| 2007 FY | 24.13 Million USD | 2060.88% |
| 2006 Q4 | 477 Thousand USD | 70.36% |
| 2006 FY | 1.11 Million USD | -22.32% |
| 2006 Q1 | 188 Thousand USD | -56.28% |
| 2006 Q2 | 170 Thousand USD | -9.57% |
| 2006 Q3 | 280 Thousand USD | 64.71% |
| 2005 Q3 | 194 Thousand USD | -59.92% |
| 2005 FY | 1.43 Million USD | -29.89% |
| 2005 Q4 | 430 Thousand USD | 121.65% |
| 2005 Q1 | 331 Thousand USD | 2.48% |
| 2005 Q2 | 484 Thousand USD | 46.22% |
| 2004 FY | 2.05 Million USD | -45.23% |
| 2004 Q4 | 323 Thousand USD | -19.05% |
| 2004 Q3 | 399 Thousand USD | -28.75% |
| 2004 Q2 | 560 Thousand USD | -27.18% |
| 2004 Q1 | 769 Thousand USD | 205.49% |
| 2003 Q2 | 1.84 Million USD | 71.53% |
| 2003 Q3 | 1.55 Million USD | -15.67% |
| 2003 Q4 | -729 Thousand USD | -146.88% |
| 2003 Q1 | 1.07 Million USD | -50.09% |
| 2003 FY | 3.74 Million USD | -60.92% |
| 2002 Q4 | 2.15 Million USD | -24.18% |
| 2002 Q2 | 2.28 Million USD | -0.78% |
| 2002 Q1 | 2.3 Million USD | -14.58% |
| 2002 Q3 | 2.84 Million USD | 24.39% |
| 2002 FY | 9.58 Million USD | -19.15% |
| 2001 Q3 | 3.37 Million USD | -7.54% |
| 2001 FY | 11.85 Million USD | 21.44% |
| 2001 Q1 | 2.13 Million USD | 1.67% |
| 2001 Q2 | 3.64 Million USD | 71.15% |
| 2001 Q4 | 2.69 Million USD | -20.12% |
| 2000 Q1 | 2.88 Million USD | 57.83% |
| 2000 Q4 | 2.09 Million USD | -21.25% |
| 2000 Q3 | 2.66 Million USD | 25.79% |
| 2000 Q2 | 2.11 Million USD | -26.54% |
| 2000 FY | 9.75 Million USD | 70.43% |
| 1999 Q2 | 1.2 Million USD | -14.29% |
| 1999 Q1 | 1.4 Million USD | 27.27% |
| 1999 FY | 5.72 Million USD | 33.16% |
| 1999 Q3 | 1.4 Million USD | 16.67% |
| 1999 Q4 | 1.82 Million USD | 30.43% |
| 1998 FY | 4.3 Million USD | 22.86% |
| 1998 Q3 | 1.3 Million USD | 18.18% |
| 1998 Q2 | 1.1 Million USD | 37.5% |
| 1998 Q1 | 800 Thousand USD | 0.0% |
| 1998 Q4 | 1.1 Million USD | -15.38% |
| 1997 Q1 | 700 Thousand USD | -12.5% |
| 1997 Q2 | 900 Thousand USD | 28.57% |
| 1997 Q3 | 1 Million USD | 11.11% |
| 1997 Q4 | 800 Thousand USD | -20.0% |
| 1997 FY | 3.5 Million USD | 9.38% |
| 1996 Q2 | 700 Thousand USD | 0.0% |
| 1996 Q1 | 700 Thousand USD | 0.0% |
| 1996 FY | 3.2 Million USD | 77.78% |
| 1996 Q3 | 1 Million USD | 42.86% |
| 1996 Q4 | 800 Thousand USD | -20.0% |
| 1995 FY | 1.8 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 110.52 Million USD | -419.96% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -3385.751% |
| Aspira Women's Health Inc. | 24.11 Million USD | -2283.205% |
| Biodesix, Inc. | 77.41 Million USD | -642.306% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -14548.825% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -6456.718% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -6456.718% |
| Bionano Genomics, Inc. | 148.99 Million USD | -285.713% |
| CareDx, Inc | 277.76 Million USD | -106.894% |
| Check-Cap Ltd. | 19.28 Million USD | -2879.655% |
| Castle Biosciences, Inc. | 242.78 Million USD | -136.708% |
| DarioHealth Corp. | 62.17 Million USD | -824.334% |
| Exact Sciences Corporation | 2.06 Billion USD | 72.11% |
| Fulgent Genetics, Inc. | 171.9 Million USD | -234.302% |
| Guardant Health, Inc. | 901.62 Million USD | 36.261% |
| ICON Public Limited Company | 755.64 Million USD | 23.947% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 47.414% |
| Illumina, Inc. | 3.81 Billion USD | 84.928% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -4808.155% |
| iSpecimen Inc. | 16.27 Million USD | -3430.605% |
| Standard BioTools Inc. | 113.48 Million USD | -406.38% |
| MDxHealth SA | 71.25 Million USD | -706.509% |
| 23andMe Holding Co. | 420.73 Million USD | -36.592% |
| Medpace Holdings, Inc. | 187.68 Million USD | -206.205% |
| Myriad Genetics, Inc. | 600.1 Million USD | 4.235% |
| Mainz Biomed B.V. | 27.15 Million USD | -2016.369% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -5362.413% |
| NeoGenomics, Inc. | 341.25 Million USD | -68.405% |
| Neogen Corporation | 405.23 Million USD | -41.815% |
| Inotiv, Inc. | 246.9 Million USD | -132.758% |
| Natera, Inc. | 938.98 Million USD | 38.797% |
| OpGen, Inc. | 30.65 Million USD | -1774.508% |
| Psychemedics Corporation | 11.33 Million USD | -4970.461% |
| Prenetics Global Limited | 60.73 Million USD | -846.194% |
| Prenetics Global Limited | 60.73 Million USD | -846.194% |
| Precipio, Inc. | 13.63 Million USD | -4113.858% |
| Personalis, Inc. | 128.14 Million USD | -348.469% |
| RadNet, Inc. | 268.87 Million USD | -113.734% |
| Sera Prognostics, Inc. | 39.91 Million USD | -1339.702% |
| Sotera Health Company | 300.46 Million USD | -91.265% |
| Neuronetics, Inc. | 82.25 Million USD | -598.63% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -3431.748% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -3431.748% |
| Trinity Biotech plc | 46.49 Million USD | -1136.017% |
| T2 Biosystems, Inc. | 41.49 Million USD | -1284.986% |
| Twist Bioscience Corporation | 354.18 Million USD | -62.258% |
| Exagen Inc. | 52.29 Million USD | -998.973% |